If you have been diagnosed with breast cancer, or you are a few years past treatment and still dealing with fatigue, you may have come across a striking claim: that ashwagandha ranked first out of fifteen plant substances for improving quality of life in breast cancer. The claim is real. It comes from a 2025 network meta-analysis. What the headline leaves out is how little evidence the ranking actually rests on.
This guide walks through that analysis, the one study underneath it, and what is and is not known about taking ashwagandha during and after breast cancer treatment. It is not a recommendation to take or avoid it. That decision belongs with your oncology team.
Key Takeaways
- A 2025 network meta-analysis ranked ashwagandha first for quality of life, fatigue, pain and nausea in breast cancer [1].
- Its ashwagandha result comes from one open-label, non-randomized trial of 100 women, and the trial authors asked for a randomized study to confirm it [2].
- Survival in that trial was 72% vs 56% at 24 months, but the difference was not statistically significant, so it is not evidence of a survival benefit.
- Most anti-cancer research on ashwagandha is in cells and animals, not people [3].
- No strong evidence supports swallowed supplements for treatment side effects, per the ASCO-endorsed guideline [4]. Talk to your oncologist before starting ashwagandha.
What the 2025 network meta-analysis found
The analysis pooled 18 studies covering 2,062 breast cancer patients and compared fifteen plant substances, including mistletoe extracts, ginseng, curcumin, ginger and soy, on patient-reported outcomes [1]. Because few of these substances were ever tested against each other directly, a network meta-analysis estimates how they compare indirectly and then ranks them with a score called SUCRA.
Ashwagandha came out on top almost everywhere. It ranked first for overall quality of life (SUCRA 99.4%), physical functioning, role functioning and emotional functioning (each 100%), and it was the top-ranked option for reducing fatigue, pain and nausea [1]. The estimated effect sizes were very large: standardized mean differences of 4.66 for quality of life, 7.78 for physical functioning and 8.10 for role functioning.
For context, by the usual convention a standardized mean difference of about 0.8 already counts as a large effect. Numbers five to ten times that size are rare for any treatment, which is the first sign that something about the underlying data deserves a closer look.
The ranking rests on a single study
The study table in the full paper lists exactly one ashwagandha trial in the network: Biswal and colleagues, from Malaysia, with 50 women in each group and a design labelled non-RCT [1]. Every ashwagandha estimate in the analysis traces back to that one study.
That trial enrolled 100 women with breast cancer of all stages, most of them stage II or III, who were starting one of two standard chemotherapy combinations [2]. Half also took ashwagandha root extract, 2 grams every 8 hours, for the whole course of chemotherapy. It was open-label, meaning everyone knew who was taking the herb, and patients were not randomly assigned to the two groups.
The results were encouraging. The group not taking ashwagandha reported significantly higher fatigue on two separate fatigue scales, and 7 of 18 symptom measures on a standard cancer quality-of-life questionnaire favored the ashwagandha group [2]. The authors also reported 24-month survival of 72% with ashwagandha and 56% without, but stated plainly that this difference was not statistically significant (p = .176). Their own conclusion was that a larger randomized trial is needed to validate the findings.
Why does the design matter so much here? Fatigue and quality of life are self-reported. When women know they are taking something they hope will help, and the comparison group knows they are not, expectation alone can shift those scores. Without randomization, the two groups may also have differed in ways the study could not measure. A single small study like this can produce an outsized effect in a network analysis, and the meta-analysis authors say as much: they write that the very large ashwagandha effect sizes warrant careful interpretation and may reflect small-study effects [1].
So the honest summary is this: the 2025 analysis searched four databases through January 2025 and found no other ashwagandha trial in breast cancer to include [1]. One promising but uncontrolled study from more than a decade ago is the whole evidence base, and a ranking built on it should be read as a reason to run a randomized trial, not as proof.
Most of the anti-cancer research is not in people
You may also see ashwagandha described as having anti-cancer properties. Nearly all of that comes from laboratory work. A scoping review of Ayurvedic adaptogens in oncology tagged 584 articles, of which ashwagandha accounted for 151 and breast cancer was the second most common cancer type; 80.3% of all the articles were in vitro studies [3].
A separate review of 272 publications on ashwagandha and cancer from 2000 to 2024 found that withaferin A, one of its compounds, was the most studied, but concluded that gaps in clinical data, pharmacokinetics, safety and toxicity are holding the field back from clinical development [5].
A result in a dish of breast cancer cells tells you a compound is worth studying. It does not tell you what a capsule from the pharmacy does inside a person who is also receiving chemotherapy, radiation or hormone therapy.
The hormone question, for hormone-sensitive cancers
Many breast cancers are hormone receptor positive, so it is reasonable to ask whether ashwagandha affects estrogen. Here the evidence points in different directions. A 2026 review focused on breast cancer describes withaferin A suppressing estrogen receptor alpha in laboratory models, and also describes ashwagandha as raising LH, FSH, estrogen and progesterone [6]. In contrast, a 2026 meta-analysis of 23 placebo-controlled trials with 1,706 participants found no effect on estradiol in either women or men [7].
Neither source settles the question for you. The placebo-controlled trials enrolled adults without cancer, so their reassuring estradiol result is not safety data for hormone-sensitive disease. We also searched for human studies of ashwagandha taken alongside tamoxifen or an aromatase inhibitor and could not locate any; what exists is computer modeling, not patients. For more on how ashwagandha interacts with hormones generally, see our guide to ashwagandha and hormonal balance.
What is known about supplements during chemotherapy
The largest prospective look at supplement use during breast cancer chemotherapy comes from SWOG S0221, which surveyed 1,134 women enrolled in a chemotherapy trial [8]. Antioxidant supplements taken before and during treatment were associated with a higher hazard of recurrence (adjusted hazard ratio 1.41, borderline significance), and vitamin B12 and iron were associated with worse outcomes; multivitamins were not. The study’s published results do not report anything about ashwagandha, so it tells us nothing about ashwagandha specifically. What it does show is that supplements during chemotherapy are not automatically harmless, which is why its authors recommended caution.
The Society for Integrative Oncology guideline on integrative therapies during and after breast cancer treatment, endorsed by the American Society of Clinical Oncology, reached a similar place: it found no strong evidence that swallowed dietary supplements help manage treatment-related side effects [4]. The approaches it did recommend for anxiety, mood and quality of life were things like meditation, yoga, music therapy and stress management.
The liver: one more reason to keep your team informed
Ashwagandha has a documented, if uncommon, link to liver injury. A 2026 scoping review found 13 publications describing 25 patients, typically developing after weeks of use, most often with a cholestatic pattern and jaundice [9]. Most people recovered after stopping, but one needed a liver transplant and three patients with pre-existing cirrhosis died. Many cancer treatments are monitored with liver blood tests, so an unexpected change needs a clear explanation, and an undisclosed supplement makes that harder. Our ashwagandha and liver health guide covers the warning signs in more detail.
If you are considering ashwagandha
- During active treatment: do not start it on your own. Bring it to your oncologist or oncology pharmacist and ask specifically about your regimen.
- On tamoxifen or an aromatase inhibitor: there is no human interaction data either way, so the decision should be made with the person managing your hormone therapy.
- After treatment: if your team is comfortable with it, the same cautions that apply to any woman still apply. See our guide to ashwagandha side effects and medication interactions.
- Always: list every supplement on your medication record, and stop and call your team if you notice yellowing skin or eyes, dark urine or persistent itching.
Frequently Asked Questions
Is ashwagandha proven to improve quality of life during breast cancer treatment?
No. A 2025 network meta-analysis ranked it first, but its ashwagandha result comes from a single open-label, non-randomized trial of 100 women, and that trial’s own authors called for a randomized study to confirm it.
Did ashwagandha improve survival in the breast cancer trial?
The trial reported 24-month survival of 72% with ashwagandha and 56% without, but the difference was not statistically significant, so it does not show a survival benefit.
Is it safe to take ashwagandha with tamoxifen or an aromatase inhibitor?
We could not find any human study that tested ashwagandha alongside tamoxifen or an aromatase inhibitor. With no data either way, this is a decision to make with your oncologist.
Does ashwagandha raise estrogen?
The evidence disagrees. A 2026 review described it as raising estrogen, while a meta-analysis of 23 placebo-controlled trials found no change in estradiol in women or men. None of those trials enrolled women with breast cancer.
Should I tell my oncologist I take ashwagandha?
Yes. Tell your oncology team about every supplement, including ashwagandha, before and during treatment, and let them decide whether it fits your regimen.
References
- Systematic review and network meta-analysis of the effects of plant active substance on quality of life in breast cancer patients. Frontiers in Pharmacology, 2025
- Effect of Withania somnifera (Ashwagandha) on the development of chemotherapy-induced fatigue and quality of life in breast cancer patients. Integrative Cancer Therapies, 2013
- A scoping review of Ayurvedic rasayana adaptogens in oncology. Journal of Ayurveda and Integrative Medicine, 2024
- Integrative Therapies During and After Breast Cancer Treatment: ASCO Endorsement of the SIO Clinical Practice Guideline. Journal of Clinical Oncology, 2018
- A bibliometric and critical trend analysis of the anti-cancer potential of Withania somnifera during 2000-2024. Naunyn-Schmiedeberg’s Archives of Pharmacology, 2026
- The interplay of Ashwagandha with hormonal dynamics and gut microbiota in women with breast cancer: a tri-axial perspective. Journal of Natural Medicines, 2026
- Hormonal Modulation with Withania somnifera: Systematic Review and Meta-Analysis of Randomized-controlled Trials. Planta Medica, 2026
- Dietary Supplement Use During Chemotherapy and Survival Outcomes of Patients With Breast Cancer Enrolled in a Cooperative Group Clinical Trial (SWOG S0221). Journal of Clinical Oncology, 2020
- Ashwagandha (Withania somnifera)-Associated Liver Injury: A Scoping Review of Clinical Characteristics and Safety Considerations. Cureus, 2026
This article is for general information and is not medical advice. It is not a substitute for guidance from your oncology team. These statements have not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.
These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure, or prevent any disease. Content is for informational purposes only and is not medical advice; consult a qualified healthcare provider before starting any supplement. As an Amazon Associate we earn from qualifying purchases.